• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Mulroy Dennis

    5/7/26 4:31:40 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARCT alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    MULROY DENNIS

    (Last)(First)(Middle)
    C/O ARCTURUS THERAPEUTICS HOLDINGS INC.
    10285 SCIENCE CENTER DRIVE

    (Street)
    SAN DIEGO CALIFORNIA 92121

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    05/01/2026
    3. Issuer Name and Ticker or Trading Symbol
    Arcturus Therapeutics Holdings Inc. [ ARCT ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Financial Officer
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Grant Levine, as attorney-in-fact for Dennis Mulroy05/07/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $ARCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARCT

    DatePrice TargetRatingAnalyst
    3/18/2026$22.00Buy
    B. Riley Securities
    1/23/2026$20.00Buy
    Roth Capital
    10/24/2025$12.00Buy → Neutral
    H.C. Wainwright
    10/23/2025$12.00Buy → Neutral
    Citigroup
    10/22/2025Buy → Neutral
    Guggenheim
    9/4/2025$60.00Buy
    H.C. Wainwright
    5/28/2025$32.00Sector Outperform
    Scotiabank
    1/28/2025$41.00Buy
    BTIG Research
    More analyst ratings

    $ARCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in New York: 2026 Jefferies Global Healthcare Conference (Presentation) Thursday, June 4, 2026 (9:20 a.m. ET) Webcast link can be found under Investor Relations/Events section of Arcturus' website. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare dis

    5/26/26 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

    Initiated enrollment (Q1 2026) earlier than expected for 12‑week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects Received regulatory direction on pediatric development strategy from FDA (Type C meeting) for ornithine transcarbamylase (OTC) deficiency program; End of Phase 2 (EOP2) meeting H2 2026 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and prov

    5/7/26 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026. Arcturus Therapeutics First Quarter 2026 Earnings Conference Call Thursday, May 7, 2026, at 4:30 p.m. ET Domestic: 1-800-579-2543 International: 1-785-424-1789 Conference ID: ARCTURUS Webcast: Link About Arcturus Founded in 2013 and based in San Diego, Cal

    4/27/26 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Arcturus Therapeutics with a new price target

    B. Riley Securities initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $22.00

    3/18/26 8:22:55 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Arcturus Therapeutics with a new price target

    Roth Capital initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $20.00

    1/23/26 8:16:17 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Arcturus Therapeutics from Buy to Neutral and set a new price target of $12.00

    10/24/25 8:56:54 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Mulroy Dennis

    4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    5/7/26 4:32:54 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Mulroy Dennis

    3 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    5/7/26 4:31:40 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Controller Roberts Joseph

    4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    12/19/25 5:22:23 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    SEC Filings

    View All

    SEC Form 10-Q filed by Arcturus Therapeutics Holdings Inc.

    10-Q - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

    5/7/26 4:14:04 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

    5/7/26 4:08:19 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcturus Therapeutics Holdings Inc.

    SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    5/7/26 3:37:51 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Sassine Andy bought $20,499 worth of shares (1,238 units at $16.56), increasing direct ownership by 0.56% to 221,764 units (SEC Form 4)

    4/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    8/20/25 4:01:44 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Sassine Andy decreased direct ownership by 0.56% to 221,764 units (SEC Form 4)

    4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

    8/19/25 4:05:30 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Leadership Updates

    Live Leadership Updates

    View All

    Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company's Board of Directors since June 2024. "Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate," said Joseph Payne, President & Chief Executive Officer of Arcturus. "We look forward to working with him as we enter a transformative yea

    2/4/25 8:30:00 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

    Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. "Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and comm

    6/20/24 8:00:00 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Appoints John Markels, Ph.D. to its Board of Directors

    Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company's vaccine franchise Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Markels will provide strategic oversight to the C

    12/13/22 8:30:00 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

    SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    11/8/24 3:17:24 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

    SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    11/5/24 6:07:26 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

    SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

    4/5/24 12:18:33 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARCT
    Financials

    Live finance-specific insights

    View All

    Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

    Initiated enrollment (Q1 2026) earlier than expected for 12‑week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects Received regulatory direction on pediatric development strategy from FDA (Type C meeting) for ornithine transcarbamylase (OTC) deficiency program; End of Phase 2 (EOP2) meeting H2 2026 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and prov

    5/7/26 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026. Arcturus Therapeutics First Quarter 2026 Earnings Conference Call Thursday, May 7, 2026, at 4:30 p.m. ET Domestic: 1-800-579-2543 International: 1-785-424-1789 Conference ID: ARCTURUS Webcast: Link About Arcturus Founded in 2013 and based in San Diego, Cal

    4/27/26 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

    ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates. "Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical d

    3/3/26 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care